Sol-Gel Technologies Ltd.

NasdaqCM:SLGL

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

💄 Cosmetics

Location

Israel

Market Cap

USD 20.87 M

Share Price

USD 7.49

Avg Daily Volume

27,038

Change (1 day)

3.74%

Change (1 year)

Change (YTD)

23.80%

Sol-Gel Technologies Ltd. Total Assets for the year ending December 31, 2024: USD 35.85 M

Sol-Gel Technologies Ltd. Total Assets is USD 35.85 M for the year ending December 31, 2024, a -20.85% change year over year. Total assets are the total value of all assets owned by a company, representing its resources.

Sol-Gel Technologies Ltd. Total Assets for the year ending December 31, 2023 was USD 45.29 M, a -2.88% change year over year.
Sol-Gel Technologies Ltd. Total Assets for the year ending December 31, 2022 was USD 46.63 M, a -32.61% change year over year.
Sol-Gel Technologies Ltd. Total Assets for the year ending December 31, 2021 was USD 69.19 M, a 16.95% change year over year.
Sol-Gel Technologies Ltd. Total Assets for the year ending December 31, 2020 was USD 59.16 M, a -3.49% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Total Assets	Accounts Payable	Short-Term Debt	Long-Term Debt

NasdaqCM: SLGL

Sol-Gel Technologies Ltd.

CEO	Mr. Moshe Arkin
IPO Date	Feb. 1, 2018
Location	Israel
Headquarters	7 Golda Meir Street
Employees	34
Sector	🏥 Health Care
Industries Pharmaceuticals 💄 Cosmetics

Description

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.